Back to Directory
Myricx Bio
London
Founded 2019
Novel ADC payloads targeting NMT enzymes in cancer
Myricx Bio is a clinical-stage biotechnology company developing a novel class of antibody-drug conjugate payloads based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival.
Its NMTi payload chemistry platform addresses limitations of existing ADC payloads, including resistance and tolerability, across multiple solid tumour types.
The company advanced a pipeline of NMTi-ADCs targeting B7-H3 and HER2. In July 2026, Novartis agreed to acquire Myricx for $1.1bn upfront.
Company Notes
Previously Known As
Myricx Pharma
Member of